Overview

A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants

Status:
Completed
Trial end date:
2018-06-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of lasmiditan on simulated driving performance in healthy participants. Participants are expected to complete each of four study periods, which will last a total of about 10 days. During this time, participants will remain in the clinical research unit. Screening must be completed within 28 days before the start of the study. Follow-up will be completed about one week after discharge.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Diphenhydramine
Lasmiditan
Promethazine